SCHEMBL1741193

SCHEMBL1741193

C=CCc1ccc(C#N)cc1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM5A P29375 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
KDM5B Q9UGL1 1/20 0.37
MRGPRX4 Q96LA9 1/20 0.35
GABRA1 P14867 1/20 0.34
GABRB2 P47870 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
HPGD P15428 1/20 0.34
KMT2A Q03164 1/20 0.34
FFAR1 O14842 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
AR P10275 3/20 0.33
GAA P10253 1/20 0.33
TSHR P16473 1/20 0.33
RECQL P46063 1/20 0.33
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9447458 0.86 GABRA1 (0.38) CYP2A6ALDH1A1MRGPRX4GABRA1GABRB2
SCHEMBL2724438 0.82 CYP2A6 (0.38) CYP2A6ALDH1A1KDM5AKDM4CKDM5B
SCHEMBL10343019 0.82 GABRA1 (0.34) GABRA1GABRB2GAAPOLB
SCHEMBL21995424 0.79 CYP2A6 (0.41) CYP2A6ALDH1A1KDM5AKDM4CKDM5B
SCHEMBL2153680 0.79 CYP2A6 (0.44) CYP2A6ALDH1A1KDM5AKDM4CKDM5B
SCHEMBL2154771 0.79 CYP2A6 (0.44) CYP2A6ALDH1A1KDM5AKDM4CKDM5B
SCHEMBL2723073 0.78 AR (0.44) ALDH1A1GABRA1GABRB2ARPOLB
SCHEMBL7651615 0.77 LOXL2 (0.41) GABRA1GABRB2LOXL2
SCHEMBL12763619 0.77 CYP2A6 (0.48) CYP2A6ALDH1A1KDM5AKDM4CKDM5B
SCHEMBL587985 0.76 KDM4C (0.33) KDM4CGABRA1GABRB2HTR2AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
EP-2390252-A1 New pyrazole derivatives Almirall, S.A. (ES) 2011-11-30 EP disclosed
EP-2390252-A1 New pyrazole derivatives Almirall, S.A. (ES) 2011-11-30 EP disclosed
WO-2011144338-A1 PYRAZOLE DERIVATIVES AS S1P1 AGONISTS ALMIRALL, S.A. (ES) 2011-11-24 WO disclosed
WO-2011144338-A1 PYRAZOLE DERIVATIVES AS S1P1 AGONISTS ALMIRALL, S.A. (ES) 2011-11-24 WO disclosed
WO-2010072352-A1 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE S1PR1, S1PR2, S1PR3 CYP2A6 3289/4885ALDH1A1 1042/4885KDM5A 4336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.